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I.	Abstract	
	 Endometrial	 cancer	 is	 the	most	 common	gynecologic	 cancer	with	54,870	cases	occurring	in	the	United	States	in	2015	and	causing	10,170	deaths,	an	18.5%	mortality	rate	(Elit	and	Reade,	2015).		Ovarian	cancer,	while	less	common,	is	much	more	fatal.	In	2015	in	the	United	States,	21,290	cases	occurred	and	resulted	in	14,180	deaths,	a	66.6%	mortality	rate.	This	mortality	rate	makes	ovarian	cancer	the	fifth	most	deadly	cancer	for	women	 in	 the	 United	 States,	 which	 is	 largely	 explained	 by	 ineffective	 screening	strategies	and	limited	treatment	possibilities	(Cramer,	2012).	Thus,	developing	effective	prevention	 strategies	 is	 especially	 important	 to	 saving	 the	 lives	 of	 women	 who	 will	develop	 ovarian	 or	 endometrial	 cancer.	Women	 taking	 combined	 oral	 contraceptives	(COCs),	 a	 type	 of	 hormonal	 birth	 control,	 have	 shown	 a	 significant	 reduced	 risk	 of	developing	ovarian	and	endometrial	cancer.	However,	 the	Centers	 for	Disease	Control	and	Prevention	 (CDC)	does	not	 currently	 recommend	 taking	COCs	 for	 the	prevention	gynecologic	cancer	(CDC,	2014a).	Since	the	efficacy	of	COCs	for	reducing	risk	of	ovarian	and	 endometrial	 cancer	 is	 well	 established,	 guidelines	 need	 to	 be	 determined	 for	populations	of	women	that	should	take	hormonal	birth	control	to	minimize	cancer	risk.	This	 paper	 highlights	 the	 current	 understanding	 of	 ovarian	 and	 endometrial	 cancer,	populations	of	women	at	highest	 risk	 for	developing	either	of	 these	 two	cancers,	 and	then	 proposes	 a	 case-control	 study	 to	 help	 determine	 which	 populations	 of	 women	should	take	hormonal	birth	control	to	reduce	their	gynecologic	cancer	risk.	
Key	words:	Endometrial	cancer,	ovarian	cancer,	hormonal	birth	control,	combined	oral	contraceptives,	risk	factors,	prevention	
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II.	Introduction	
	 Women	have	been	using	birth	control	pills	as	a	primary	method	of	contraception	since	 they	 were	 first	 developed	 in	 the	 1960’s.	 In	 the	 fifty	 years	 since	 the	 pill	 was	introduced,	overwhelming	scientific	data	has	revealed	many	unintended	health	benefits	to	 women	 currently	 taking	 oral	 contraceptives	 and	 past	 users.	 A	 focal	 point	 in	epidemiologic	study	is	the	effect	of	combined	oral	contraceptives	(COCs),	which	contain	estrogen	and	progestin,	on	the	prevention	of	ovarian	and	endometrial	(uterine)	cancer.	While	COCs	are	most	commonly	advertised	for	contraceptive	health,	it	may	be	time	to	emphasize	their	cancer	prevention	benefits.			 There	 are	many	 different	 forms	 of	 combined	 oral	 contraceptives	 and	 types	 of	hormonal	birth	control,	however	for	consistency	and	simplicity	this	paper	will	focus	on	the	 traditional	 cyclical	 combined	 oral	 contraceptive.	 Cyclical	 COCs	 consist	 of	 three	weeks	 of	 a	 daily	 estrogen	 and	 progestin	 pill	 and	 one	 week	 of	 placebo	 (Brynhildsen,	2014).	 Additionally,	 “COCs”	 refer	 to	 all	 types	 of	 cyclical	 COCs,	which	means	 the	 term	does	not	 distinguish	between	brands	 that	may	have	 slightly	 different	 hormone	doses	and	different	generations	of	progestins.	Other	methods	of	administration	of	hormonal	birth	control,	such	as	the	patch,	the	vaginal	ring,	the	intrauterine	device,	or	injectables,	are	 excluded	 because	 their	 effects	 compared	 to	 COCs	may	 be	 confounded	 by	 patient	deviation	 in	 their	prescribed	use,	despite	 that	 all	 the	administration	methods	use	 the	same	hormones.			The	Centers	for	Disease	Control	and	Prevention	(CDC)	provides	information	on	possible	 ways	 to	 reduce	 the	 risk	 of	 developing	 ovarian	 cancer.	 The	 CDC	 currently	suggests	that	having	used	birth	control	pills	may	reduce	a	woman’s	risk	of	developing	
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ovarian	cancer,	but	it	then	warns	that	this	method	(among	others)	should	not	be	used	as	a	way	to	prevent	ovarian	cancer.	With	so	much	knowledge	available	concerning	the	positive	 consequences	 of	 taking	 hormonal	 birth	 control,	 it	 is	 time	 to	 re-evaluate	 the	indications	for	oral	contraceptive	use.	While	there	are	contraindications	to	taking	COCs	in	some	women,	many	studies	have	shown	that	the	benefits	far	outweigh	the	risks	for	most	women.	Identifying	the	population	of	women	who	would	most	benefit	from	taking	COCs	from	the	women	who	are	at	risk	of	complications	is	the	next	step	in	reducing	the	incidence	of	ovarian	and	endometrial	cancer.	Further,	not	all	 forms	of	hormonal	birth	control	 are	 equivalent,	 so	 determining	 the	 COC	with	 the	 highest	 benefit-to-risk	 ratio	will	be	important	to	optimizing	the	efficacy	of	cancer	prevention.					
Opportunities	for	Gynecologic	Cancer	Prevention		Ovarian	 and	 endometrial	 cancer	 are	 the	 two	 main	 cancers	 that	 exhibit	 much	lower	 incidences	 among	 women	 who	 have	 taken	 or	 who	 are	 currently	 taking	 COCs.	Attention	 on	 prevention	 for	 these	 two	 cancers	 is	 important	 because	 few	 successful	prevention	 strategies	 exist	 and	 treatment	 at	 onset	 is	 limited.	 American	 Cancer	Screening	 Guidelines	 currently	 do	 not	 recommend	 screening	 for	 women	 with	 an	average	or	 increased	 risk	of	developing	endometrial	 cancer	 (Smith	et	 al.,	 2016).	Only	women	with	a	very	high	risk,	such	as	those	with	Lynch	syndrome	or	who	have	another	high-risk	 genetic	 mutation	 are	 recommended	 for	 screening	 at	 35	 years	 of	 age.	 No	effective	screening	is	available	for	ovarian	cancer	for	women	at	average	risk.	Successful	screening	strategies	are	still	being	investigated,	but	have	not	yet	proven	to	be	effective	in	 early	 diagnosis	 of	 ovarian	 cancer.	 Some	promising	 results	 have	 come	 from	 the	UK	
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Collaborative	Trial	 of	Ovarian	Cancer	 Screening	 (UKCTOCS),	which	 has	 published	 the	results	 of	 a	massive	 trial	 testing	 the	 efficacy	of	multimodal	 screening	 strategy	 (MMS)	with	cancer	antigen	125	(CA	125)	and	transvaginal	ultrasound	(TVU)	(Smith	et	al.,	2016	as	 reviewed	 in	 Jacobs	 et	 al.,	 2016).	 When	 considering	 confounding	 factors,	 the	researchers	found	a	20%	reduction	in	deaths	from	ovarian	cancer	through	use	of	MMS,	however	 further	 follow-up	 is	 necessary	 before	 the	 results	 are	 used	 to	 establish	 new	screening	 guidelines.	 The	 current	 lack	 of	 successful	 screening	 techniques	 emphasizes	the	 importance	 of	 focusing	 on	 known,	 effective	 methods	 of	 preventing	 ovarian	 and	endometrial	 cancer.	 The	 birth	 control	 pill	 has	 proved	 time	 and	 again	 to	 dramatically	reduce	 the	 risk	 of	 developing	 these	 two	 types	 of	 gynecologic	 cancer	 and	 its	 role	 in	cancer	 prevention	 is	 ever	 more	 important	 due	 to	 the	 lagging	 progress	 in	 screening	options	(Bahamondes	et	al.,	2015;	Beavis	et	al.,	2016;	Brynhildsen,	2014;	Cibula	et	al.,	2010;	Davidson	and	Moorman,	2014;	Maguire	and	Westhoff,	2011).			 Additionally,	 while	 screening	 techniques	 have	 yet	 to	 be	 refined	 to	 lower	 the	number	 of	 deaths	 from	 ovarian	 cancer,	 some	 prophylactic	 surgeries	 such	 as	salpingectomy	(removal	of	a	fallopian	tube)	have	reduced	the	risk	of	women	developing	ovarian	 cancer.	 A	 population-based	 study	 compared	 the	 risk	 of	 developing	 ovarian	cancer	 among	 women	 who	 underwent	 hysterectomy	 (removal	 of	 the	 uterus),	sterilization,	bilateral	salpingectomy,	unilateral	salpingectomy,	and	women	who	had	no	surgery	 (Falconer	 et	 al.,	 2015).	 All	 surgeries	 lowered	 the	 risk	 of	 developing	 ovarian	cancer	 and	 salpingectomy	was	 the	most	 effective	 at	 decreasing	 risk	 (HR	=	0.65,	 95%	CI	=	0.52	 to	 0.81).	 Bilateral	 salpingectomy	 was	 more	 effective	 than	 unilateral	salpingectomy	with	a	further	50%	reduction	in	risk.	Increasing	evidence	suggests	most	
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ovarian	 cancers	 originate	 in	 the	 fallopian	 tube,	 which	 explains	 why	 removing	 both	fallopian	 tubes	 produces	 dramatically	 lower	 rates	 of	 ovarian	 cancer.	 Women	 who	qualify	 as	 high-risk	 for	 ovarian	 cancer	 (known	 carriers	 of	mutations	 such	 as	 BRCA1,	BRCA2	or	Lynch	mutations)	can	reduce	their	risk	by	undergoing	prophylactic	bilateral	salpingo-oophorectomy	(removal	of	the	two	fallopian	tubes	and	ovaries)	(Walker	et	al.,	2015).	Prophylactic	removal	of	the	uterus,	fallopian	tubes,	and	ovaries	or	prevention	by	using	 birth	 control	 pills	 are	 currently	 the	 most	 effective	 risk-reducing	 strategies	 for	ovarian	 and	 endometrial	 cancer.	 It	 would	 be	 beneficial	 to	 many	 at-risk	 women	 to	establish	 guidelines	 for	 prevention	 of	 these	 cancers	 with	 one	 or	 both	 of	 these	approaches.		
Overview	of	Ovarian	and	Endometrial	Cancer	Endometrial	cancer	 is	the	most	common	gynecologic	cancer,	with	54,870	cases	occurring	in	the	United	States	in	2015	and	causing	10,170	deaths,	an	18.5%	mortality	rate	(Elit	and	Reade,	2015).		Ovarian	cancer,	while	less	common,	is	much	more	fatal.	In	2015	 in	 the	 United	 States,	 21,290	 cases	 of	 ovarian	 cancer	 occurred	 and	 there	 were	14,180	deaths,	a	66.6%	mortality	rate.	This	mortality	rate	for	ovarian	cancer	makes	it	the	 fifth	 most	 deadly	 cancer	 for	 women	 in	 the	 United	 States	 (Cramer,	 2012).	Endometrial	and	ovarian	cancer	are	often	grouped	together	when	studying	prevention	strategies	 because	 the	 two	 cancers	 are	 believed	 to	 share	 similar	 etiologies	 and	 risk	factors.		
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Characterizing	Endometrial	Cancer		There	are	two	types	of	endometrial	cancer,	Type	I	and	Type	II.	Type	II	is	much	less	common	than	Type	I	with	an	incidence	of	10-20%	of	all	cases,	but	Type	II	results	in	40%	of	deaths	(Setiawan	et	al.,	2013).	Type	 II	endometrial	 tumors	are	usually	serous	carcinomas	 or	 clear	 cell	 whereas	 Type	 I	 tumors	 are	 usually	 endometrial	adenocarcinomas.	The	origin	of	Type	I	tumors	is	believed	to	be	triggered	by	unopposed	estrogen	 stimulation	 and	 is	 frequently	 preceded	 by	 endometrial	 hyperplasia.	 Since	estrogen	promotes	cell	proliferation	through	a	variety	of	genetic	signaling	mechanisms,	high	 doses	 of	 unopposed	 estrogen	 increase	 the	 likelihood	 of	 conferring	 oncogenic	mutations	and	eliminating	 tumor-suppressive	mutations	 in	 endometrial	 tissue	 (Hecht	and	 Mutter,	 2006).	 Examples	 of	 mutations	 most	 commonly	 found	 in	 Type	 I	 cancers	include	 microsatellite	 instability	 (MSI)	 or	 alterations	 of	 PTEN,	 K-ras,	 and	 β-catenin.	Progestins	decrease	the	risk	of	endometrial	cancer	by	inhibiting	the	effects	of	estrogen	(as	reviewed	in	Hecht	and	Mutter,	2006).	Further,	progestins	modulate	higher	levels	of	expression	of	Bcl-2	and	BAX,	resulting	in	higher	levels	of	cell	death	and	thus	reducing	the	 chance	 of	 survival	 of	 cells	with	 cancerous	mutations.	 Conversely,	 Type	 II	 cancers	most	commonly	contain	mutations	of	p53	and	have	aneuploidy.	Type	II	tumors	are	not	caused	by	unopposed	estrogen	stimulation	as	are	Type	I	tumors.		
	
Gauging	Endometrial	Cancer	Risk	by	Factors	Affecting	Hormone	Levels	Both	Type	I	and	II	endometrial	cancers	share	similar	risk	factors,	which	include	obesity,	 nulliparity,	 early	 menarche	 (first	 menstrual	 period),	 late-onset	 menopause,	older	age	(≥55	years),	and	use	of	tamoxifen,	all	of	which	induce	variations	in	hormone	
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levels	(as	reviewed	in	Morice	et	al.,	2016).	Abnormally	high	estrogen	levels	and/or	low	levels	 of	 progesterone	 is	 a	 leading	 indication	 for	 increased	 risk	 of	 developing	endometrial	 cancer	 (Kaaks	 et	 al.,	 2002).	 The	 theory	 underlying	 the	 increased	 risk	 is	known	as	the	“unopposed	estrogen	theory,”	which	suggests	that	the	proliferative	effects	of	 estrogen	 increase	 the	 likelihood	 of	 developing	 oncogenic	mutations.	 Progesterone	induces	anti-proliferative	effects,	which	is	why	progesterone	is	considered	to	“oppose”	estrogen	 and	 decrease	 the	 risk	 of	 developing	 endometrial	 cancer.	 Consequently,	identifying	conditions	that	cause	these	specific	changes	 in	hormone	 levels	will	help	 in	determining	populations	of	women	most	at	risk	for	developing	endometrial	cancer	and	who	would	most	benefit	from	hormonal	therapy.	Obese	women	are	particularly	likely	to	develop	endometrial	cancer,	with	a	2.4	to	4.5	 increased	 risk	 of	 both	 types	 of	 endometrial	 cancer	 and	 are	 up	 to	 seven	 times	 as	likely	to	develop	Type	I	endometrial	cancer	as	women	of	a	healthy	weight	(as	reviewed	in	Beavis	 et	 al.,	 2016).	This	 large	 increase	 in	 risk	 is	 likely	 explained	by	 the	metabolic	changes	that	occur	in	obese	women,	which	affect	the	natural	balance	of	hormone	levels	(Kaaks	et	al.,	2002).	There	are	three	main	metabolic	consequences	of	obesity	supported	by	the	unopposed	estrogen	theory.	First,	obesity	increases	insulin	levels,	which	inhibits	production	of	sex-hormone	binding	globulin	(SHBG)	(as	reviewed	in	Kaaks	et	al.,	2002).	SHBG	 is	 a	 carrier	 glycoprotein	 that	binds	 to	 and	 inhibits	 the	availability	 of	hormones	such	 as	 estrogens	 and	 androgens	 (Bulut	 et	 al.,	 2015).	 Thus,	 lower	 levels	 of	 SHBG	increase	 the	 levels	 of	 active	 estrogen,	 which	 then	 increases	 proliferative	 factors	 that	may	 lead	 to	 the	 development	 of	 endometrial	 cancer.	 The	 two	 other	 metabolic	consequences	 of	 obesity	 which	 may	 contribute	 to	 endometrial	 cancer	 are	 increased	
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levels	 of	 androgens	 (a	 result	 of	 high	 insulin	 and	 insulin-like	 growth	 factor	 1)	 and	increased	levels	of	estrogens	(as	a	result	of	conversion	from	androgens)	(as	reviewed	in	Kaaks	 et	 al.,	 2002).	 These	 mechanisms	 are	 consistent	 with	 the	 finding	 that	 obese	women	are	especially	prone	to	developing	the	estrogen-dependent	Type	I	endometrial	cancer.	The	close	association	between	obese	women	and	hormonal	deregulation	makes	them	a	potential	beneficiary	of	COC	therapy	for	cancer	prevention.			Polycystic	ovarian	syndrome	(PCOS),	an	endocrine	disease	that	affects	6-10%	of	women,	 is	 another	 risk	 factor	 associated	with	 an	 increased	 incidence	 of	 endometrial	cancer.	This	hypothesis	 is	more	 controversial	 than	others	because	women	with	PCOS	have	 high	 rates	 of	 obesity,	 a	 known	 cause	 of	 endometrial	 cancer.	 Additional	confounding	factors	associated	with	PCOS	 include	Type	2	Diabetes,	 inflammation,	and	metabolic	syndrome.	The	pathology	of	endometrial	cancer	from	PCOS	is	thought	to	be	a	result	 of	 high	 levels	 of	 estrogen	 relative	 to	 low	 levels	 of	 progesterone	 during	anovulatory	cycles	(cycles	in	which	no	ovum	is	released	from	the	ovary).	Regardless	of	whether	PCOS	alone	is	a	high	risk	factor,	women	with	PCOS	are	more	likely	to	develop	endometrial	cancer	and	should	be	considered	a	higher	risk	population.	Another	high	risk	group	for	endometrial	cancer	is	women	with	Lynch	syndrome,	which	results	in	mutations	of	the	mismatch	repair	genes	MLH1,	MSH2,	MSH6,	and	PMS2	(Hall	et	al.,	2016).	Women	with	Lynch	syndrome	have	a	15-60%	chance	of	developing	endometrial	 adenocarcinoma	 (Type	 I	 tumors).	 Hysterectomy	 and	 salpingo-oophorectomy	 are	 often	 recommended	 for	 women	 with	 these	 high-risk	 genetic	mutations.	 However,	 it	 would	 be	 interesting	 to	 investigate	 the	 effectiveness	 of	 COCs	alone	 or	 in	 combination	 with	 prophylactic	 surgery	 to	 better	 understand	 how	
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endometrial	cancer	incidence	varies	between	treatment	possibilities.	If	COCs	were	used	among	 all	 women	 with	 high-risk	 genetic	 mutations,	 it	 is	 possible	 incidence	 of	endometrial	 cancer	would	 diminish	 enough	 so	 that	 the	 benefits	 of	 surgery	 no	 longer	outweighed	 the	 accompanying	 risks.	 On	 the	 other	 hand,	 it	 is	 possible	 surgical	intervention	 in	 combination	 with	 COC	 use	 is	 necessary	 for	 the	 highest	 reduction	 in	incidence	of	endometrial	cancer.	Endometriosis,	 an	 inflammatory	 disease	 which	 results	 in	 the	 growth	 of	endometrial	 tissue	 outside	 the	 uterus	 and	 affects	 6-10%	 of	 women,	 is	 a	 suggested	precursor	to	endometrial	cancer	(Mogensen	et	al.,	2016).	A	cohort	study	by	Mogensen	et	al.	 found	 that	women	with	endometriosis	had	a	40%	 increased	 risk	 for	developing	endometrial	 cancer.	 However,	 only	 endometrioid	 and	 clear-cell	 tumors	 resulted	 in	higher	 incidence	 among	 women	 with	 endometriosis	 compared	 to	 the	 general	population.	 The	 relationship	 between	 endometriosis	 and	 endometrial	 cancer	 is	commonly	 explained	 by	 the	 unopposed	 estrogen	 theory	 and	 there	 is	 additional	indication	 that	 the	 endometrium	 even	 develops	 resistance	 to	 the	 anti-proliferative	effects	 of	 progesterone	 (Kim	 et	 al.	 2013,	 as	 reviewed	 in	Mogensen	 et	 al.,	 2016).	 This	proposed	etiology	is	consistent	with	the	theories	supporting	the	relationship	between	obesity	 and	 increased	 incidence	 of	 endometrial	 cancer.	 Furthermore,	 COCs	 and	progestin	 therapy	are	 the	preferred	 treatments	 for	 the	pain	 caused	by	 endometriosis	and	are	well-regarded	for	 their	safety	and	efficacy	(Berlanda	et	al.,	2016).	Since	these	treatments	are	already	widely	used	among	women	suffering	 from	endometriosis,	 it	 is	practical	 to	 encourage	 their	 continued	 use	with	 knowledge	 of	 their	 added	 benefit	 to	reducing	the	risk	of	developing	endometrial	and	ovarian	cancer.		
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Additionally,	 the	 incidence	of	 endometrial	 cancer	 is	much	higher	 among	white	women	(more	than	77%	of	cases)	and	among	postmenopausal	women	(more	than	79%	of	 cases).	 Incidence	 is	 also	 higher	 in	 developed	 countries	 and	 Northern	 European	populations	 than	 in	 developing	 countries	 (Cramer,	 2012).	 The	 much	 higher	 risk	 for	endometrial	 cancer	 among	 these	 population	 groups	 suggests	 they	 may	 be	 likely	candidates	 for	a	study	that	observes	 the	risk-reducing	effect	of	COCs.	Advocating	COC	use	 among	 nulliparous,	 white,	 obese,	 postmenopausal,	 or	 women	 who	 had	 early	menarche,	endometriosis,	PCOS,	Lynch	Syndrome,	or	other	high-risk	genetic	mutations	may	yield	the	largest	net	reduction	in	cases	of	endometrial	cancer.			
Characterizing	Ovarian	Cancer	Similar	 to	 endometrial	 cancer,	 ovarian	 cancer	 has	 been	 the	 subject	 of	 many	studies	seeking	to	develop	a	comprehensive	understanding	of	its	etiology,	risk	factors,	and	prevention	strategies.	The	two	most	common	types	of	ovarian	cancer	are	ovarian	epithelial	cancer	(OEC)	and	borderline	tumors	of	the	ovary	(BOT)	(Schüler	et	al.,	2013).	While	OEC	and	BOT	share	some	histologic	features,	OEC	is	much	more	lethal	than	BOT,	with	a	mean	survival	of	44%	and	95%,	respectively		(Bonome	et	al.,	2005	as	reviewed	in	Schüler	 et	 al.,	 2013).	 There	 are	 numerous	 subcategories	 of	 OEC,	 including	 serous	ovarian	tumors,	endometrioid	tumors,	clear	cell	ovarian	tumors,	and	mucinous	tumors	(Schüler	 et	 al.,	 2013).	 OEC	 may	 also	 be	 categorized	 into	 Type	 I	 and	 Type	 II	 tumors	(Kurman	et	al.,	2011	as	reviewed	in	Schüler	et	al.,	2013).	Type	I	is	less	aggressive	than	Type	 II	 and	 consists	 of	 low-grade	 serous,	 low-grade	 endometrioid,	 clear	 cell	 and	mucinous	 carcinomas,	 and	 Brenner	 tumors.	 These	 tumors	 are	 usually	 slow	 growing,	
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relatively	stable	and	generally	present	early.	On	the	other	hand,	the	malignant	Type	II	OEC	 tumors	 are	 comprised	 of	 high-grade	 serous,	 high-grade	 endometrioid,	carcinosarcomas,	and	undifferentiated	carcinomas.	Type	II	OEC	tumors	present	in	late	stages	of	the	cancer	and	are	genetically	unstable.	The	high	lethality	of	OEC	tumors	and	the	difficulty	in	providing	successful	treatment	stresses	the	importance	of	emphasizing	prevention	strategies,	particularly	among	the	highest	risk	populations.		
Gauging	Ovarian	Cancer	Risk	by	Factors	Affecting	Hormone	Levels	Many	 of	 the	 increased	 risk	 factors	 as	well	 as	 risk-reducing	 factors	 for	 ovarian	cancer	 are	 the	 same	 as	 for	 endometrial	 cancer.	 Family	 history	 of	 ovarian	 cancer	 is	considered	 one	 of	 the	 strongest	 indications	 for	 developing	 ovarian	 cancer,	with	 first-degree	 relatives	 carrying	 as	much	as	 a	3.6	 fold	higher	 risk	 than	 those	with	no	 family	history	(as	reviewed	in	Hunn	and	Rodriguez,	2012).	Consistent	with	the	indications	for	ovarian	cancer	as	a	hereditary	disease	 is	 the	higher	prevalence	of	BRCA1	and	BRCA2	mutations	among	women	with	ovarian	cancer.	Women	carrying	a	BRCA1	mutation	have	a	30%	higher	lifetime	risk	of	developing	ovarian	cancer	than	the	general	population	and	women	 with	 a	 BRCA2	 mutation	 have	 a	 27%	 increased	 risk	 (Ford	 et	 al.,	 1998,	 as	reviewed	in	Hunn	and	Rodriguez,	2012).			Another	factor	which	increases	the	risk	of	both	endometrial	and	ovarian	cancer	is	 Lynch	 Syndrome	 (as	 reviewed	 in	 Hunn	 and	 Rodriguez,	 2012).	Women	with	 Lynch	syndrome	have	an	increased	lifetime	risk	of	12%	for	ovarian	cancer,	which	is	less	than	the	risk	of	developing	endometrial	cancer,	but	still	significant.	Since	women	with	Lynch	
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syndrome	 have	 both	 a	 significantly	 elevated	 risk	 for	 developing	 ovarian	 and	endometrial	cancer	they	should	be	considered	a	particularly	high-risk	population.			Gonadal	hormones	also	play	a	significant	role	in	the	progression	and	prevention	of	 ovarian	 cancer.	 Estrogen	 has	 primarily	 been	 associated	 with	 increased	 risk	 for	ovarian	cancer,	as	post-menopausal	women	taking	estrogen	supplements	may	have	up	to	 a	 two-fold	 risk	 increase	 (as	 reviewed	 in	Hunn	and	Rodriguez,	 2012).	On	 the	other	hand,	progestins	have	been	shown	to	produce	 large	protective	effects	against	ovarian	cancer.	 The	 protective	 effect	 of	 progestins	 in	 hormonal	 birth	 control	 is	 thought	 to	mitigate	 and	 supersede	 the	 carcinogenic	 effect	 of	 estrogen.	 Finally,	 many	 different	studies	have	presented	evidence	 for	and	against	 the	carcinogenic	effect	of	androgens,	but	 the	 relationship	 between	 androgens	 and	 the	 development	 of	 ovarian	 cancer	remains	inconclusive	(Risch,	1998,	Modugno,	2004,	Olsen	et	al.,	2008,	and	Greer	et	al.,	2005	as	reviewed	in	Hunn	and	Rodriguez,	2012).						Endometriosis	 is	an	additional	condition	associated	with	a	two-fold	 increase	 in	risk	of	ovarian	cancer	compared	to	the	general	population	(Hunn	and	Rodriguez,	2012).	How	endometriosis	causes	ovarian	cancer	has	not	yet	been	determined,	although	two	theories	have	been	proposed,	one	suggesting	that	chronic	inflammation	associated	with	endometriosis	 induces	 cancerous	 growth	 and	 the	 other	 attributing	 resistance	 to	progesterone	 as	 the	 reason	 for	 the	 increased	 likelihood	of	 developing	ovarian	 cancer	(Mogensen	et	al.,	2016).	As	mentioned	earlier,	hormonal	contraceptives	are	one	of	the	most	 common	 treatments	 for	 pelvic	 pain	 and	 suppression	 of	 endometriosis.	 Thus,	hormonal	birth	control	could	kill	three	birds	with	one	stone	by	reducing	the	discomfort	caused	by	endometriosis	and	minimizing	the	risk	of	ovarian	and	endometrial	cancer.				
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Other	 factors	 presumed	 to	 moderately	 increase	 the	 risk	 of	 ovarian	 cancer	include	obesity,	pelvic	inflammatory	disease	(PID),	and	the	use	of	talcum	powder	(talc)	(Hunn	and	Rodriguez,	2012).	Various	studies	have	suggested	obese	women	have	a	1.2	to	 2-fold	 increase	 in	 risk	 of	 developing	 ovarian	 cancer	 compared	 to	 the	 general	population,	although	obese	women	who	had	taken	hormone	replacement	therapy	were	not	found	to	have	any	increased	risk	in	developing	ovarian	cancer	(as	reviewed	in	Hunn	and	Rodriguez,	2012).	PID	 is	 thought	 to	contribute	 to	ovarian	cancer	 through	 the	up-regulation	of	the	inflammatory	response	and	as	such,	more	cases	of	PID	are	associated	with	an	increasing	risk	of	ovarian	cancer.	One	case	study	found	a	2.46-fold	increase	in	risk	of	developing	ovarian	cancer	among	women	who	had	five	or	more	occurrences	of	PID.	Lastly,	 talc	has	been	shown	 to	 increase	 the	 risk	of	ovarian	cancer	by	as	much	as	33%,	 a	 risk	 that	 could	 easily	 be	 eliminated	 by	 discontinuing	 use	 of	 the	 carcinogen	(Cramer	et	al.,	1982,	Chang	et	al.,	1997,	Harlow	et	al.,	1992	as	 reviewed	 in	Hunn	and	Rodriguez,	2012).	Table	1	lists	the	increased,	decreased,	and	indeterminate	risk	factors	for	 epithelial	 ovarian	 cancer,	 nearly	 all	 of	which	 are	 shared	with	 endometrial	 cancer	with	 the	 exception	 that	 PCOS	 increases	 risk	 for	 only	 endometrial	 cancer	 (Hunn	 and	Rodriguez,	2012).	
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Table	1.	Overview	of	the	primary	factors	which	increase	or	decrease	risk	of	epithelial	ovarian	cancer	(Hunn	and	Rodriguez,	2012).	 		
	
	
	
	
	
	
	
	
	
	
	
Gonadal	Hormones	Since	 combined	oral	 contraceptives	 provide	 the	most	 promise	 as	 a	 prevention	strategy	for	ovarian	cancer,	it	is	necessary	to	understand	the	hormones	closely	linked	to	promoting	 or	 inhibiting	 ovarian	 cancer	 development.	 Gonadotropin-releasing	hormones	 (GnRH),	 follicle	 stimulating	 hormone	 (FSH),	 luteinizing	 hormone,	 (LH),	estrogens,	 progestogens,	 and	 androgens	 are	most	 significant	 to	 the	 elucidation	of	 the	pathology	 of	 ovarian	 and	 endometrial	 cancer	 (as	 reviewed	 in	 Schüler	 et	 al.,	 2013).	GnRH	I	regulates	the	release	of	gonadotropin	from	the	pituitary	gland,	but	the	effect	of	GnRH	on	promoting	or	 inhibiting	ovarian	cancer	 is	debated.	Studies	have	shown	both	an	anti-carcinogenic	effect	of	GnRH	I	and	II	by	inducing	cell	cycle	arrest	and	apoptosis,	
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while	other	studies	have	found	a	carcinogenic	effect	of	GnRH	II	(So	et	al.,	2008,	Emons	et	al.,	1993,	Emons	et	al.,	1990,	Emons	et	al.,	2000,	and	Ling	et	al.,	2011	as	reviewed	in	Schüler	et	al.,	2013).		FSH	targets	its	receptors	on	granulosa	cells	and	LH	targets	its	receptors	on	theca	cells,	 the	signaling	mechanism	of	which	modulates	 the	production	of	ovarian	steroids	(Schüler	 et	 al.,	 2013).	 The	 increased	 incidence	 of	 FSH	 and	 LH	 receptors	 has	 been	explored	 for	 its	 possible	 contribution	 to	 OEC	 and	 BOT,	 but	 various	 studies	 show	conflicting	 evidence	 of	 their	 role	 in	 causing	 cancer.	 Many	 studies	 have	 found	correlations	 between	 overexpression	 of	 FSH-R	 and	 LH-R	 and	 higher	 expression	 of	proto-oncogenes	such	as	EGRF,	c-myc	and	Her2/neu-receptor	and	treatment	with	FSH	and	LH	produced	a	higher	expression	of	β-Catenin,	MEIS1,	cyclin	G2,	insulin-like	growth	factor	1	(IGF-1),	and	β-1	integrin	(as	reviewed	in	Schüler	et	al.,	2013).	Further	analysis	is	necessary	 to	understand	 the	 role	of	FSH	and	LH	 in	ovarian	cancer	before	potential	hormonal	 treatments	may	 be	 developed	 to	 increase	 or	 decrease	 the	 levels	 to	 a	 non-hazardous	amount.	In	contrast	to	FSH	and	LH,	estrogen	is	known	to	play	a	distinguished	role	in	the	development	 of	 OEC.	 Estrogen	 stimulates	 both	 growth	 and	 invasion	 of	 OEC	 cells	 (as	reviewed	in	Schüler	et	al.,	2013).	The	mechanisms	by	which	estrogen	stimulates	growth	are	 linked	 to	 the	proteins	Ezrin,	Fibulin,	Cathepsin	D	and	kallikrein	in	addition	 to	up-regulating	 the	growth	 factors	EGF,	TGF-alpha,	 IGF,	and	 IL-6.	 Interestingly,	estrogen	 in	OEC	may	negate	the	anti-proliferative	effect	of	progesterone	and	GnRH.	The	combined	regulatory	 effects	 of	 estrogen	 and	 progesterone	 have	 important	 implications	 for	
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establishing	 the	 optimal	 type	 of	 hormone	 and	 dosing	 in	 the	 birth	 control	 pill	 for	preventing	ovarian	cancer.		Progesterone	 is	 an	 effective	 hormone	 in	 reducing	 cancer	 risk	 because	 of	 its	contribution	to	growth	suppression	and	apoptosis	in	ovarian	cancer	cells	(as	reviewed	in	 Schüler	 et	 al.,	 2013).	 The	 protective	 effects	 of	 progesterone	 are	 thought	 to	 be	involved	with	the	cAMP-mediated	activation	of	progesterone	receptor	B	(PGR-B),	which	results	in	cell	cycle	arrest,	cellular	senescence	and	the	suppression	of	tumorigenicity	of	ovarian	cancer	cells.	A	meta-analysis	from	2013	found	that	ovarian	cancer	patients	with	higher	 levels	 of	 progesterone	 were	 expected	 to	 have	 higher	 survival	 than	 ovarian	cancer	 patients	 with	 lower	 levels	 of	 progesterone,	 which	 supports	 the	 molecular	understanding	of	the	progesterone	pathway	(Zhao	et	al.,	2013).		
Theories	on	Etiology	of	Ovarian	Cancer	Although	 specific	 links	 between	 ovarian	 cancer	 and	 particular	 molecular	pathways	have	been	 established,	 the	 general	 etiology	 of	 ovarian	 cancer	 is	 still	 up	 for	debate.	Four	theories	currently	hold	the	most	merit,	although	the	degree	to	which	each	supports	 the	 development	 of	 ovarian	 cancer	 is	 debated.	 The	 leading	 theories	 are	 the	incessant	ovulation	theory,	the	fallopian	tube	theory,	the	gonadotropin	theory,	and	the	androgen/progesterone	 theory	 (Schüler	 et	 al.,	 2013).	 The	 incessant	 ovulation	 theory	was	first	proposed	in	1971	by	Fathalla	et	al.,	which	describes	how	women	who	undergo	many	 ovulations	 in	 their	 lifetime	 experience	 higher	 rates	 of	 trauma	 to	 the	 ovarian	epithelium	 as	 a	 consequence	 of	 releasing	 the	 ovum	 and	 necessitating	 cellular	 repair	
17	
(Fathalla,	1971).	Thus,	higher	rates	of	cellular	regeneration	and	DNA	synthesis	logically	increase	the	risk	of	a	mutation	that	will	lead	to	ovarian	cancer.		The	 fallopian	 tube	 theory	 is	 relatively	 new	 and	 has	 only	 gained	 traction	 in	ovarian	 cancer	 research	 during	 the	 past	 few	 years.	 An	 increasing	 number	 of	 studies	have	shown	that	high-grade	serous	ovarian	epithelial	cancer	originates	in	the	fallopian	tube,	rather	than	the	ovarian	epithelium	as	previously	believed	(Kuhn	et	al.,	2012).	This	theory	suggests	that	a	hostile	environment	in	the	fallopian	tube	such	as	reactive	species	in	 follicular	 fluid	 and	 microenvironmental	 changes	 from	 tearing	 the	 ovarian	 surface	epithelium	 is	 the	 origin	 of	 ovarian	 epithelial	 cancer.	 The	 reason	why	 cancerous	 cells	originating	 from	 the	 fallopian	 tube	 migrate	 to	 the	 ovaries	 for	 further	 growth	 is	 still	under	investigation.		The	third	theory	regarding	gonadotropin	suggests	that	higher	levels	of	FSH	and	LH	 stimulate	 the	 ovarian	 surface	 epithelium,	 increasing	 the	 risk	 of	 ovarian	 epithelial	cancer	(Schüler	et	al.,	2013).	FSH	is	thought	to	suppress	apoptosis,	stimulate	expression	of	vascular	endothelial	growth	factor	A	(VEGFA),	and	induce	angiogenesis,	all	of	which	promote	 the	 development	 of	 ovarian	 cancer	 (Bhartiya	 and	 Singh,	 2015).	 Further	support	 for	 the	 gonadotropin	 hypothesis	 is	 provided	 by	 conditions	 that	 result	 in	abnormally	high	levels	of	FSH	as	well	as	a	higher	 incidence	of	ovarian	cancer,	such	as	women	of	older	age	and	elevated	amounts	of	FSH	in	ovarian	cyst	and	peritoneal	fluid.	As	 a	 side	 note,	 PCOS	 results	 in	 elevated	 amounts	 of	 FSH,	 but	 the	 condition	 is	 only	correlated	with	 a	 significant	 increase	 in	 risk	 for	 endometrial	 cancer	 and	 not	 ovarian	cancer	(Barry	et	al.,	2014).	Conversely,	conditions	that	result	in	abnormally	low	levels	of	FSH	are	associated	with	reduced	incidence	of	ovarian	cancer,	such	as	breast-feeding	
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and	multi-parity,	which	notably	are	also	conditions	in	which	a	female	does	not	ovulate,	supporting	the	original	incessant	ovulation	theory.	Risch	 first	 introduced	 the	 androgen/progesterone	 theory	 in	 1998,	 which	suggests	that	ovarian	cancer	occurs	as	a	result	of	high	androgen	stimulation	of	ovarian	epithelial	 cells	 and	 depleted	 progesterone	 concentrations	 which	 elicit	 protective	benefits	against	ovarian	epithelial	cancer	(Risch,	1998).	However,	the	clarity	of	the	role	of	androgens	in	promoting	ovarian	epithelial	cancer	is	disputed,	as	some	studies	have	found	higher	risk	among	women	with	higher	levels	of	androgen,	while	others	found	an	inverse	relationship	(as	reviewed	in	Schüler	et	al.,	2013).		
Arguments	Against	Combined	Oral	Contraceptives	While	the	risk	reduction	of	ovarian	and	endometrial	cancer	is	a	tempting	reason	(among	 many	 other	 health	 benefits)	 to	 begin	 use	 of	 COCs,	 there	 are	 a	 number	 of	contraindicating	 risk	 factors	 that	must	 be	 carefully	weighed	 against	 the	 benefits.	 The	most	serious	risk	factor	incurred	by	taking	COCs	is	an	increase	in	the	risk	of	developing	venous	 thromboembolism	 (VTE)	 (Brynhildsen,	 2014).	 Risk	 of	 VTE	 increases	 with	higher	 concentrations	 of	 estrogen,	 which	 is	 why	 the	 estrogen	 component	 has	 been	lowered	 to	 the	 concentrations	most	 commonly	used	 today	 (15-30	µg).	Progestins	are	believed	 to	 counteract	 the	 estrogen-induced	 risk	 increase	 of	 VTE,	 although	 recent	evidence	shows	that	different	types	of	progestins	vary	 in	their	ability	to	minimize	the	risk	 of	 VTE.	 COCs	 containing	 third	 and	 fourth	 generation	 progestins,	 such	 as	desogestrel,	gestodene,	etonogestrel,	and	drospirenone,	have	higher	incidences	of	VTE	than	 COCs	 containing	 earlier	 generations	 of	 progestins,	 such	 as	 levonorgestrel,	
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norethisterone,	and	norgestimate	 (Lidegaard	et	al.,	2012,	as	 reviewed	 in	Brynhildsen,	2014).	 Table	 2	 highlights	 the	 relative	 risk	 of	 VTE	 for	 women	 taking	 these	 various	categories	 of	 progestins.	 Despite	 these	 indications,	 the	 relative	 risk	 of	 VTE	 is	 still	extremely	low	with	2-10	cases	expected	per	10,000	users	of	COCs,	compared	to	never-users	at	2-3	cases	per	10,000.	Thus,	COCs	should	be	considered	safe	for	users	who	do	not	have	a	high	risk	of	developing	VTE,	namely	those	with	a	history	of	VTE,	those	with	first-degree	 relatives	 with	 VTE,	 and	 obese	 women.	 Without	 taking	 any	 COCs,	 obese	women	 already	 have	 an	 elevated	 three-fold	 risk	 of	 developing	 VTE	 compared	 to	 the	general	population,	but	this	risk	jumps	to	a	10	to	24-fold	increase	with	the	use	of	COCs.	In	summary,	COCs	recommended	to	the	general	population	should	be	of	 low	estrogen	dosage	(15-30	µg)	and	contain	first	or	second-generation	progestins.						
Table	2.		Risk	of	developing	venous	thromboembolism	in	a	year	according	to	the	European	Medicines	Agency	(as	reviewed	in	Brynhildsen,	2014).	
	A	 second	 contraindication	 to	 taking	 COCs	 is	 the	 possible	 increase	 in	 risk	 of	developing	breast	cancer	 (Gierisch	et	al.,	2013).	An	evaluation	of	a	combination	of	29	case-control	 studies,	 14	 cohort	 studies,	 and	 one	 pooled	 analysis	 revealed	 a	 small,	increased	 risk	 of	 developing	 breast	 cancer	 among	women	who	 had	 or	 currently	 use	
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COCs	 (OR,	 10.8;	 95%	 CI,	 1.00-1.17).	 On	 the	 other	 hand,	 there	 have	 been	 numerous	studies	 which	 suggest	 there	 is	 no	 significant	 increase	 in	 risk	 of	 breast	 cancer	 from	taking	 COCs	 or	 if	 there	 is,	 the	 risk	 increase	 is	 very	 slight	 (Davidson	 and	 Moorman,	2014).	 For	 those	 studies	 that	 have	 found	 a	 very	 slight	 increase	 in	 the	 risk	 of	 breast	cancer,	the	risk	was	shown	to	be	highest	during	current	use	of	COCs	and	diminish	to	no	increase	in	risk	by	ten	years	after	discontinuation	of	use.		This	evidence	implicates	that	COCs	may	not	be	 an	 ideal	 recommendation	 for	women	at	 a	higher	 risk	of	developing	breast	cancer,	such	as	BRCA1	and	BRCA2	carriers,	but	this	risk	must	be	balanced	with	the	 increased	 likelihood	 of	 these	 carriers	 to	 develop	 ovarian	 cancer.	 While	 breast	cancer	is	much	more	common	than	ovarian	cancer,	the	risk	increase	of	breast	cancer	is	much	 smaller	 relative	 to	 the	 large	 risk	 reduction	 in	 ovarian	 cancer	 by	 taking	 COCs.	Consequently,	 it	 is	 difficult	 to	 offer	 a	 recommendation	 one	 way	 or	 another	 as	 each	patient’s	relative	risk	for	certain	cancers	must	be	balanced	with	the	risks	they’re	willing	to	forgo	by	taking	or	not	taking	COCs.		
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III.	Experimental	Study	
Experimental	Rational		
Aim	1	
Establish	 the	populations	of	women	who	would	most	benefit	 from	taking	combined	oral	
contraceptives	in	order	to	prevent	ovarian	cancer		
Aim	2	
Establish	 the	populations	of	women	who	would	most	benefit	 from	taking	combined	oral	
contraceptives	in	order	to	prevent	endometrial	cancer	
	
Prediction	“Ever	use”	of	hormonal	birth	control	pills	containing	estrogen	and	progestins,	as	defined	 by	 a	 year	 or	more	 of	 continuous	 use,	 will	 significantly	 reduce	 the	 chance	 of	women	 developing	 endometrial	 or	 ovarian	 cancer	 in	 all	 populations	 studied	 (first	degree	 relative	 family	 history,	 BRCA	 1	 or	 2	 carriers,	 Lynch	 Syndrome,	 nulliparous,	infertile,	 early	 age	 at	 menarche,	 late	 age	 at	 menopause,	 estrogen	 hormone	replacements,	endometriosis,	and	obesity).			
Experimental	Design	The	 following	 case-control	 study	 will	 be	 carried	 out	 to	 help	 establish	recommendations	for	certain	populations	of	women	to	take	hormonal	birth	control	 in	order	to	reduce	their	risk	of	developing	endometrial	or	ovarian	cancer.	The	design	may	be	applied	to	each	of	the	subsequent	populations	of	women:	first	degree	relative	family	history,	 BRCA	 1	 or	 2	 carriers,	 Lynch	 Syndrome,	 nulliparous,	 infertile,	 early	 age	 at	
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menarche,	 late	 age	at	menopause,	 estrogen	hormone	 replacements,	 endometriosis,	 or	obesity.	 This	 case-control	 study	 will	 look	 at	 the	 risk	 of	 developing	 endometrial	 and	ovarian	cancer	independently.		The	 study	 will	 look	 at	 “ever	 use”	 of	 estrogen/progesterone	 birth	 control	 and	how	the	treatment	affects	the	risk	of	developing	ovarian	cancer	in	women	with	a	strong	family	 history	 of	 ovarian	 cancer,	 defined	 as	 at	 least	 one	 first-degree	 relative	 with	ovarian	 cancer.	 Study	 investigators	 will	 contact	 gynecologic	 oncologists	 practicing	 in	the	United	States	and	ask	 them	to	refer	patients	with	ovarian	cancer	 to	participate	 in	the	study.	Healthy	women	will	be	randomly	selected	throughout	the	United	States	and	will	 be	 recruited	 to	 participate	 through	 phone	 call	 solicitations.	 The	 study	 aims	 to	recruit	 300	women	with	 ovarian	 cancer	 and	 300	 healthy	women.	Women	 older	 than	forty	 years	 of	 age	 and	who	have	not	 undergone	 any	 type	of	 prophylactic	 surgery	 are	eligible	 to	 participate.	 All	 relatives	 will	 be	 excluded	 from	 the	 study.	 Women	 in	 the	control	group	(healthy	women)	who	have	bleeding	after	menopause	or	three	or	more	of	the	 following	warning	 signs	 of	 ovarian	 cancer	will	 be	 excluded:	 pain	 in	 the	 pelvic	 or	abdominal	area,	back	pain,	bloating,	feeling	full	quickly	while	eating,	passing	urine	very	frequently	or	often,	constipation,	or	diarrhea	(CDC,	2014b).		For	the	case-control	study	on	 endometrial	 cancer,	 women	 in	 the	 control	 group	 who	 have	 one	 or	 more	 of	 the	following	 warning	 signs	 of	 endometrial	 cancer	 will	 be	 excluded:	 abnormal	 vaginal	discharge	or	bleeding	(particularly	after	menopause),	or	pain	or	pressure	in	the	pelvis	(CDC,	 2014a).	 Finally,	 all	women	who	 have	 a	 history	 of	 use	 of	 any	 type	 of	 hormonal	birth	control	other	than	combined	oral	contraceptives,	such	as	the	patch,	vaginal	ring,	intrauterine	device,	or	injectables	will	be	excluded	from	the	study.	
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Once	 all	 cases	 and	 controls	 are	 recruited,	 complete	 medical	 history	 will	 be	collected	from	subjects	who	agree	to	release	their	medical	record	for	the	purpose	of	the	study.	 History	 of	 use	 of	 a	 combined	 oral	 contraceptive	 for	 at	 least	 a	 year	 will	 be	organized	 according	 to	 Table	 3	 in	 order	 to	 calculate	 the	 odds	 ratio	 of	 developing	ovarian	 cancer	 for	women	who	 have	 taken	 COCs	 compared	 to	women	who	 have	 not	taken	COCs.	Since	ovarian	cancer	is	a	rare	disease,	the	odds	ratio	(OR)	will	be	similar	to	the	relative	risk.	
Table	 3.	 Example	 of	 how	 to	 organize	 data	 for	 a	 case-control	 study	 to	 determine	 odds	 of	 developing	ovarian	cancer	among	women	who	have	a	first-degree	relative	with	ovarian	cancer.			
	 Estrogen/Progesterone	Birth	Control	Pill	Use	(≥	1	Year)		 Yes	 No	Ovarian	Cancer	 A	 B	Healthy	 C	 D		 		Odds	Ratio					p(cancer	+	pill	use)/p(healthy	+	pill	use)	=	odds	of	having	cancer	on	pill																					p(cancer	+	no	pill	use)/p(healthy	+	no	pill	use)	=	odds	of	having	cancer	with	no	pill	OR	=	(odds	of	having	cancer	on	pill)/(odds	of	having	cancer	with	no	pill)		OR	=	(A/C)/(B/D)		 95%	Confidence	Interval	of	ln(OR):	
ln 𝑂𝑅 − 1.96  !! + !! + !! + !! 	to	 ln 𝑂𝑅 + 1.96  !! + !! + !! + !! 	If	COCs	reduce	the	odds	of	developing	ovarian	cancer,	the	odds	ratio	should	be	less	than	1.	 If	COCs	have	no	effect	on	the	odds	of	developing	ovarian	cancer,	 the	odds	
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should	 be	 1.	 If	 COCs	 increase	 the	 odds	 of	 developing	 ovarian	 cancer,	 the	 odds	 ratio	should	be	greater	than	1.		
	
Null	hypothesis	There	 is	 no	 effect	 of	 COCs	 on	 the	 odds	 of	 developing	 ovarian	 cancer	 among	women	 with	 one	 or	 more	 first-degree	 relatives	 with	 ovarian	 cancer	 compared	 to	healthy	women	of	the	same	population.		OR=1	is	in	the	95%	Confidence	Interval		
Alternative	hypothesis	There	 is	 an	 effect	 of	 COCs	 on	 the	 odds	 of	 developing	 ovarian	 cancer	 among	women	 with	 one	 or	 more	 first-degree	 relatives	 with	 ovarian	 cancer	 compared	 to	healthy	women	of	the	same	population.	OR=1	is	not	in	95%	Confidence	Interval		 Table	 4	 and	 the	 accompanying	 calculations	 provide	 a	 hypothetical	 example	 of	how	the	odds	ratio	will	be	calculated.	Odds	of	developing	ovarian	cancer	are	0.46	 for	women	taking	COCs	(who	have	a	first-degree	relative	with	ovarian	cancer)	than	that	of	women	not	taking	COCs	of	the	same	population.	The	95%	confidence	interval	(CI)	of	the	odds	ratio	(0.32,	0.67)	 indicates	the	odds	of	ovarian	cancer	are	significantly	 lower	for	women	 taking	 COCs	 compared	 to	 women	 not	 taking	 COCs	 because	 the	 CI	 does	 not	contain	1.			
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Table	4.	Hypothetical	data	 for	a	case-control	study	to	determine	odds	of	developing	ovarian	cancer	for	women	who	have	taken	COCs	compared	to	women	who	have	not	taken	COCs	(all	of	whom	have	a	first-degree	 relative	with	 ovarian	 cancer).	 In	 this	 example,	 odds	 of	 developing	 ovarian	 cancer	 are	 0.46	 for	women	taking	COCs	compared	to	women	not	taking	COCs.			
	 Estrogen/Progesterone	Birth	Control	Pill	Use	(≥	1	Year)		Yes	 No	Ovarian	Cancer	 195	 105	Healthy	 240	 60		OR	=	(195/240)/(105/60)	OR	=	0.46		
ln 0.46 − 1.96  !!"# + !!"# + !!"# + !!" 	to	 ln 0.46 + 1.96  !!"# + !!"# + !!"# + !!" 		-1.15	to	-0.407	!	e-1.15	=	0.32		to			e-0.407	=	0.67	CI:	0.32	to	0.67		
Benefits	of	Experimental	Design		 There	are	a	number	of	advantages	to	running	a	case-control	study,	which	include	the	 need	 for	 many	 fewer	 subjects	 than	 prospective	 studies,	 a	 much	 shorter	 time	 to	complete	 the	analysis	 since	 the	 study	 is	not	dependent	on	disease	progression,	 and	a	low	 chance	 of	 losing	 patients	 to	 follow-up.	 Additionally,	 the	 study	may	 be	 applied	 to	many	 different	 populations	 of	 women,	 enabling	 a	 broad	 survey	 of	 potential	beneficiaries	 of	 combined	 oral	 contraceptives.	 Finally,	 case-control	 studies	 have	 a	relatively	low	cost	in	comparison	to	prospective	studies	or	controlled	trials.			
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Drawbacks	and	Confounding	Variables		
	 There	 is	 a	 potential	 for	 recall	 bias	 as	 cases	 and	 controls	may	 not	 give	 equally	detailed	 or	 accurate	 information	 regarding	 their	 history	 of	 using	 COCs	 since	 women	with	 ovarian	 cancer	 may	 be	 more	 interested	 in	 supporting	 the	 study.	 Additionally,	patients	only	become	a	part	of	the	study	through	physician	referral	and	as	it	is	difficult	to	detect	ovarian	cancer,	physicians	could	miss	referring	patients	who	actually	did	have	ovarian	 cancer.	 Likewise,	 control	 patients	 could	 unknowingly	 have	 ovarian	 cancer.	Patients	were	also	not	matched	for	race	due	to	the	small	population	surveyed	and	the	type	 of	 analysis	 used,	 so	 a	 difference	 in	 race	 between	 the	 control	 and	 disease	populations	may	confound	the	odds	ratio.	 	Lastly,	women	without	ovarian	cancer	only	become	part	of	the	study	if	they	frequently	stay	at	home	to	answer	the	phone	and	this	selection	factor	was	not	applied	to	the	cases.	
	
Assumptions		 The	 study	 assumes	 cases	 and	 controls	 are	 randomly	 selected	 from	 the	populations	 and	 are	 representative	 of	 women	 across	 the	 United	 States	 who	 have	 at	least	 one	 first-degree	 relative	 with	 ovarian	 cancer.	When	 selecting	 for	 controls,	 it	 is	assumed	subjects	do	not	differ	systematically	from	the	cases	in	any	way	except	for	the	absence	of	ovarian	cancer.		
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Discussion:	The	Pill	and	the	Population		 The	 results	 of	 this	 study	will	 provide	 a	 direction	 for	 developing	 a	 prospective	study	and	more	thorough	analyses	of	which	populations	of	women	would	most	benefit	from	 taking	COCs.	The	 study	 is	 limited	 in	 that	 it	does	not	 consider	duration	of	use	of	COCs,	 daily	 hormone	 dosing,	 or	 type	 of	 progestin	 used,	 but	 these	 questions	 may	 be	answered	in	future	experiments.	Once	the	populations	are	determined	that	would	most	benefit	 from	 taking	 COCs,	 specific	 parameters	 for	 COC	 recommendation	 should	 be	determined	(e.g.	age	of	women	when	they	begin	COCs,	age	at	discontinuation,	method	of	administration,	 type	 of	 phasic	 regimen,	 who	 should	 be	 recommended	 COCs	 in	combination	 with	 prophylactic	 surgery	 and	 at	 what	 age,	 COCs	 in	 combination	 with	other	therapies,	and	necessity	of	the	COCs	among	low	risk	populations).		Interestingly,	 a	 retrospective	 study	 found	 that	 obese	women	with	 endometrial	cancer	(BMI	≥30)	who	used	low-dose	aspirin	following	a	hysterectomy	with	subsequent	chemo	or	radiotherapy	had	a	significantly	higher	survival	rate	(HR	0.43,	P=0.27)	than	women	who	did	not	use	low-dose	aspirin	(Matsuo	et	al.,	2016).	Obese	women	tend	to	suffer	 from	more	 inflammation	 than	women	with	 healthy	BMIs,	which	 indicates	why	aspirin,	 an	 anti-inflammatory	 drug,	 showed	 a	 significant	 effect	 in	 only	 obese	women.	Excessive	inflammation	is	an	enabling	characteristic	to	many	of	the	hallmarks	of	cancer,	such	as	sustaining	proliferative	signaling,	promoting	angiogenesis,	resisting	cell	death,	and	 inducing	 genome	 instability	 and	 mutations	 (Hanahan	 and	 Weinberg,	 2011).	 By	reducing	 inflammation,	 aspirin	 may	 reduce	 inflammatory	 mechanisms	 that	 promote	these	hallmarks,	thereby	increasing	survival	among	obese	women	who	are	particularly	prone	to	inflammation.	Additionally,	low-dose	aspirin	use	among	younger	women	(≤60	
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years),	 women	 with	 Type	 I	 endometrial	 cancer,	 and	 women	 who	 had	 postoperative	whole	pelvic	radiotherapy	had	significantly	higher	survival	rates	than	their	counterpart	groups;	 older	 women,	 Type	 II	 endometrial	 cancer,	 and	 alternative	 postoperative	therapies,	 respectively	 (Matsuo	 et	 al.,	 2016).	 The	 preventative	 benefit	 of	 a	 low-dose	aspirin	 regimen	 is	 a	 potential	 therapy	 to	 lower	 the	 risk	 of	 developing	 endometrial	cancer	in	addition	to	reducing	the	risk	of	recurrence.	Exploring	the	effect	of	combining	low-dose	 aspirin	 therapy	 with	 COCs	 among	 women	 experiencing	 excessive	inflammation	 is	 a	 potential	 treatment	 that	 should	 be	 evaluated	 for	 the	 prevention	 of	endometrial	cancer.	Once	 the	 parameters	 for	 which	 populations	 of	 women	 should	 take	 COCs	 are	well-established,	the	CDC	should	update	its	recommendations	for	prevention	methods	of	 ovarian	 and	 endometrial	 cancer.	 Further,	 as	 hormonal	 birth	 control	 will	 likely	 be	recommended	to	many	large	populations	of	women	for	cancer	prevention	(also	due	to	its	 many	 other	 health	 benefits),	 access	 should	 be	 increased	 to	 make	 it	 more	 readily	available.	 Possibilities	 include	 making	 hormonal	 birth	 control	 over-the-counter	 and	mandating	that	insurance	provides	free	hormonal	contraception	coverage.	Additionally,	an	 emphasis	 should	 be	 placed	 on	 educating	 primary	 care	 physicians,	obstetricians/gynecologists,	 patient	 populations,	 and	 government	 officials	 about	 the	many	benefits	of	hormonal	birth	control,	which	would	help	to	maximize	the	number	of	women	electing	to	take	hormonal	contraception.		
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